Compare PMT & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMT | ACHV |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.7M | 726.5M |
| IPO Year | 2009 | 2018 |
| Metric | PMT | ACHV |
|---|---|---|
| Price | $7.48 | $6.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $10.38 | ★ $14.15 |
| AVG Volume (30 Days) | ★ 2.8M | 1.3M |
| Earning Date | 10-29-2026 | 11-13-2026 |
| Dividend Yield | ★ 21.68% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $351,067,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.23 | N/A |
| P/E Ratio | $18.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.70 | $2.62 |
| 52 Week High | $13.80 | $8.64 |
| Indicator | PMT | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 45.37 | 44.06 |
| Support Level | $6.70 | $5.96 |
| Resistance Level | $9.80 | $7.30 |
| Average True Range (ATR) | 0.22 | 0.38 |
| MACD | 0.12 | 0.04 |
| Stochastic Oscillator | 81.76 | 43.93 |
PennyMac Mortgage Investment Trust is a specialty finance company that invests mainly in residential mortgage loans and mortgage-related assets. The company's operations include activities such as the production and servicing of financial securities based on residential loans and the pooling and reselling of high-credit-quality mortgages. The company operates through three segments: correspondent production, credit-sensitive strategies, interest-rate-sensitive strategies. The Credit sensitive strategies segment generates income via investments in CRT arrangements, subordinate MBS, distressed loans, and real estate.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.